Johnson & Johnson (JNJ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. (OTCQB:IPATF). The new deal offers Janssen an exclusive access to an array of novel and monoclonal antibodies against an undisclosed target. The company will also have an option to acquire all commercial rights to such antibodies. However, the companies did not disclose the financial terms and conditions of the collaboration.

ImmunoPrecise has entered into the deal through its subsidiary Talem Therapeutics, which is mainly engaged in the discovery and development of early antibodies. The collaboration is expected to draw synergies from both the companies’ expertise in different areas. ImmunoPrecise focuses on providing multi-format, agnostic human monoclonal antibodies. The company recently provided update about its research activities pertaining COVID-19. ImmunoPrecise is using multitargeting approach to combine different SARS-CoV-2 spike protein forms.

READ FULL ARTICLE HERE